RecruitingNot ApplicableNCT07131059

MRD-positive AML Clinical Study

MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

120 participants

Start Date

May 11, 2024

Study Type

INTERVENTIONAL

Conditions

AML, Adult

Summary

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This study is testing treatments for people with acute myeloid leukemia (AML) who are in remission but still have detectable traces of cancer in their body — known as MRD-positive (measurable residual disease) — to try to prevent the cancer from coming back. **You may be eligible if...** - You have AML (not the APL subtype) - You are currently in complete remission (no visible leukemia cells) - Tests show small amounts of remaining cancer in the blood or bone marrow (MRD-positive) - You are 14 or older **You may NOT be eligible if...** - You are planning to have a stem cell transplant within the next 4 weeks - You have APL (acute promyelocytic leukemia) - Your doctor does not consider you suitable for inclusion based on your overall condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIvosidenib

500mg d1-28

DRUGGilteritinib

120mg d1-28

DRUGVenetoclax

400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21

DRUGAvapritinib

200mg d1-28.

DRUGDaunorubicin

45mg/m2/d d1-2;

DRUGCytarabine

100mg/m2/d d1-5

DRUGIdarubicin

10mg/m2/d d1-2

DRUGMTZ

8mg/m2/d d1-2

DRUGHHT

2mg/m2/d d1-5

DRUGAzacitidine

75mgd/m2 d1-7.

Locations(1)

Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07131059

Related Trials

Revumenib in Combination With 7+3 + Midostaurin in AML

NCT063134372 locations

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

NCT071326841 location

Quality of Life-Guided Transfusion in Refractory MDS or AML

NCT073281911 location

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

NCT0637757921 locations

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

NCT0653376113 locations